Growth hormone treatment for idiopathic short stature - Implications for practice and policy

被引：21
作者：
Cuttler, L [1 ]
Silvers, JB [1 ]
机构：
[1] Rainbow Babies & Childrens Hosp, Dept Pediat, Div Endocrinol, Cleveland, OH 44106 USA
来源：
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE | 2004年 / 158卷 / 02期
关键词：
D O I：
10.1001/archpedi.158.2.108
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：108 / 110
页数：3
相关论文
共 28 条
[21]   The psychosocial consequences of short stature: a review of the evidence [J].
Sandberg, DE ;
Voss, LD .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 16 (03) :449-463
[22]  
*US FDA, FDA DRUG APPR LIST
[23]   Growth hormone therapy for the short normal child: Who needs it and who wants it? The case against growth hormone therapy [J].
Voss, LD .
JOURNAL OF PEDIATRICS, 2000, 136 (01) :103-106
[24]   Psychosocial outcome of children evaluated for short stature [J].
Zimet, GD ;
Owens, R ;
Dahms, W ;
Cutler, M ;
Litvene, M ;
Cuttler, L .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 1997, 151 (10) :1017-1023
[25]  
ZIMET GD, 1995, J DEV BEHAV PEDIATR, V16, P264
[26]  
1994, MED LETT DRUGS THER, V36, P77
[27]  
1999, MED LETT DRUGS THER, V41, P2
[28]  
FDA TALK PAPER FDA A
123